LON:GNS Genus Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Genus plc Please log in to your account or sign up in order to add this asset to your watchlist. GBX 2,504 +28.00 (+1.13%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range 2,504▼ 2,55250-Day Range 2,234▼ 2,76252-Week Range 2,186▼ 6,310Volume98,907 shsAverage Volume100,456 shsMarket Capitalization£1.65 billionP/E Ratio44.56Dividend Yield1.28%Price TargetGBX 5,348 ProfileAnalyst RatingsChartCompetitorsDividendInsider TradesHeadlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genus and its competitors with MarketBeat's FREE daily newsletter. Email Address GNS Stock Forecast (MarketRank)Overall MarketRank™1.92 out of 5 starsAnalyst Opinion: 3.3Community Rank: 4.7Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 3.3 Analyst's Opinion Consensus RatingGenus has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 5,310, Genus has a forecasted upside of 112.1% from its current price of GBX 2,504.Amount of Analyst CoverageGenus has only been the subject of 1 research reports in the past 90 days. Previous Next 4.7 Community Rank Outperform VotesGenus has received 349 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGenus has received 146 “underperform” votes. (Add your “underperform” vote.)Community SentimentGenus has received 70.51% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Genus and other stocks. Vote “Outperform” if you believe GNS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 1.7 Dividend Strength Dividend YieldGenus pays a meaningful dividend of 1.28%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthGenus does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Genus is 0.57%. This payout ratio is at a healthy, sustainable level, below 75%. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genus insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Genus is 44.56, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 13.72.Price to Earnings Ratio vs. SectorThe P/E ratio of Genus is 44.56, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 12.33.Price to Earnings Growth RatioGenus has a PEG Ratio of 2.50. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGenus has a P/B Ratio of 3.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Genus (LON:GNS)Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers semen sexing, in reproductive, and other technical services to farmers. Genus plc has a strategic collaboration with Beijing Capital Agribusiness Co. Ltd to pursue the porcine reproductive respiratory syndrome virus resistant regulatory and development work in China. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.Read More GNS Stock News HeadlinesJune 23, 2022 | finance.yahoo.comGold Standard Diagnostics, a Eurofins Technologies Company, Announces a PCR Assay for the Detection of the Monkeypox and Orthopox Virus - Yahoo FinanceJune 15, 2022 | bloomberg.comWHO to Convene Emergency Meeting on Monkeypox Amid Spread - BloombergJune 11, 2022 | washingtonpost.comReview | At the Kennedy Center, Hancock's well-worn tricks still surprise - The Washington PostJune 3, 2022 | washingtonpost.comOpinion | Monkeypox is a reminder of lurking global health threats. Prepare, or else. - The Washington PostJune 2, 2022 | reuters.comU.S. national spelling bee pits kids ages 7-15 trying to spell success - ReutersMay 30, 2022 | finance.yahoo.comSeveral Health Benefits of Macadamia increased the demand for Macadamia Milk Market: Future Market Insights Report - Yahoo FinanceMay 26, 2022 | bloomberg.comRoche Develops New Tests to Help Scientists Track Monkeypox - BloombergMay 15, 2022 | cnet.comNo Tears, No Mess: How to Cut an Onion Without Crying - CNETMay 13, 2022 | techcrunch.comWeAre8 launches crowdfunder for its social media app, where users are paid to watch ads - TechCrunchMay 9, 2022 | businessinsider.comBorneo 'mystery monkey' could be rare hybrid of two different species - Business InsiderMay 8, 2022 | africa.businessinsider.com'Mystery monkey' spotted in a Borneo forest could be a rare hybrid of two different species, new study says - Business Insider AfricaMay 7, 2022 | msn.comThese plant and animal species have been named after celebrities - msnNOWApril 25, 2022 | latimes.comResearchers discover new deep-sea creature in Monterey Bay - Los Angeles TimesSee More Headlines Industry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:GNS CUSIPN/A CIKN/A Webwww.genusplc.com Phone+44-1256-347100FaxN/AEmployees3,400Year FoundedN/ACompany Calendar Ex-Dividend for 3/31 Dividend3/03/2022Dividend Payable3/31/2022Today6/24/2022Next Earnings (Estimated)9/08/2022Price Target and Rating Average Stock Price ForecastGBX 5,310 High Stock Price ForecastGBX 5,740 Low Stock Price ForecastGBX 4,500 Forecasted Upside/Downside+113.6%Consensus RatingModerate Buy Rating Score (0-4)2.6 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio44.56 Forward P/E Ratio26.58 P/E Growth2.5Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio37.36 Current Ratio1.77 Quick Ratio1.13 Sales & Book Value Annual Sales£569.80 million Price / Sales2.89 Cash FlowGBX 69.98 per share Price / Cash Flow35.78 Book ValueGBX 778.60 per share Price / Book3.22Miscellaneous Outstanding Shares65,770,000Free FloatN/AMarket Cap£1.65 billion OptionableNot Optionable BetaN/A Genus Frequently Asked Questions Should I buy or sell Genus stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genus in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Genus stock. View analyst ratings for Genus or view top-rated stocks. What is Genus' stock price forecast for 2022? 4 Wall Street analysts have issued 1 year target prices for Genus' shares. Their GNS stock forecasts range from GBX 4,500 to GBX 5,740. On average, they expect Genus' stock price to reach GBX 5,310 in the next year. This suggests a possible upside of 112.1% from the stock's current price. View analysts' price targets for Genus or view top-rated stocks among Wall Street analysts. How has Genus' stock price performed in 2022? Genus' stock was trading at GBX 4,938 at the beginning of the year. Since then, GNS shares have decreased by 49.3% and is now trading at GBX 2,504. View the best growth stocks for 2022 here. When is Genus' next earnings date? Genus is scheduled to release its next quarterly earnings announcement on Thursday, September 8th 2022. View our earnings forecast for Genus. How often does Genus pay dividends? What is the dividend yield for Genus? Genus announced a dividend on Thursday, February 24th. Shareholders of record on Thursday, March 3rd will be given a dividend of GBX 10.30 per share on Thursday, March 31st. This represents a dividend yield of 0.33%. The ex-dividend date of this dividend is Thursday, March 3rd. The official announcement can be seen at this link. View Genus' dividend history. Is Genus a good dividend stock? Genus(LON:GNS) pays an annual dividend of GBX 0.32 per share and currently has a dividend yield of 1.28%. The dividend payout ratio of Genus is 0.57%. This payout ratio is at a healthy, sustainable level, below 75%. View Genus' dividend history. Who are Genus' key executives? Genus' management team includes the following people: Mr. Stephen Wilson, CEO & Exec. Director (Age 62, Pay $1.67M)Ms. Alison Henriksen, CFO & Exec. Director (Age 55, Pay $1.13M)Dr. William Christianson, Chief Operating OfficerDr. Elena Rice, Head of R&D and Chief Scientific OfficerMr. Dan Hartley, Group Gen. Counsel & Company Sec.Ms. Angelle R. Rosata, Group HR DirectorMr. Jerry Thompson, Chief Operating Officer of Genus ABS BeefDr. Nate Zwald, Chief Operating Officer of Genus ABS DairyMs. Janet Duane, Group Financial Controller Who are some of Genus' key competitors? Some companies that are related to Genus include BTG (BTG), Abcam (ABC), Oxford Nanopore Technologies (ONT), Trillium Therapeutics (TRIL), Cronos Group (CRON), Concordia International (CXR), BELLUS Health (BLU), Biotest Aktiengesellschaft (BIO), MorphoSys (MOR), Ergomed (ERGO), Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Pfenex (PFNX) and Dyne Therapeutics (DYN). View all of GNS's competitors. What other stocks do shareholders of Genus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genus investors own include Clinigen Group (CLIN), Glencore (GLEN), Tesco (TSCO), AstraZeneca (AZN), British American Tobacco (BATS), Cronos Group (CRON), Dairy Crest Group (DCG), Debenhams (DEB), Diageo (DGE) and Experian (EXPN). What is Genus' stock symbol? Genus trades on the London Stock Exchange (LON) under the ticker symbol "GNS." How do I buy shares of Genus? Shares of GNS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Genus' stock price today? One share of GNS stock can currently be purchased for approximately GBX 2,504. How much money does Genus make? Genus (LON:GNS) has a market capitalization of £1.65 billion and generates £569.80 million in revenue each year. How many employees does Genus have? Genus employs 3,400 workers across the globe. How can I contact Genus? Genus' mailing address is Matrix House, Basing View, BASINGSTOKE, RG21 4DZ, United Kingdom. The official website for Genus is www.genusplc.com. The company can be reached via phone at +44-1256-347100. This page (LON:GNS) was last updated on 6/25/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
